Leerink raised the firm’s price target on Axsome Therapeutics (AXSM) to $150 from $110 and keeps an Outperform rating on the shares. The ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Equities researchers at Leerink Partnrs lifted their Q3 2025 earnings estimates for Cencora in a research report issued on ...

Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Cullinan Therapeutics in a report released ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...

Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform to Outperform. As of January 29, 2025, the average one-year price ...